Investors / United States / Eos BioInnovation
Eos BioInnovation
Venture capital · Cambridge, MA, United States · North America
Eos BioInnovation incubates, launches and builds early-stage companies emerging from academic labs and research institutions in regenerative medicine. It invests in and adds strategic and operational support to portfolio companies developing cell, gene and tissue therapies and enabling technologies.
Invests inHealthcare & Biotech
In its own wordsregenerative medicinecell therapygene therapybiotechlife sciencestherapeutics
Your fit with Eos BioInnovation
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsEos BioInnovation lists 6 checked portfolio companies on its own site and is named in 2 funding rounds, 1 of them as lead. Its most frequent entry is Seed, 100% of the companies with a known first round. Its largest theme is Healthcare & Biotech (100%). 75% of its companies are based in United States. It invests most often alongside Creative Destruction Lab, Lifespan Vision Ventures and Axial.
Counts come from funding rounds that name Eos BioInnovation, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Entry stage
share of companies by the stage of its first roundShow as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 100% |
| Series A | 0% |
| Series B | 0% |
| Growth | 0% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 0 | 0 |
| '25 | 0 | 0 |
| '26 | 2 | 1 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 8th | 6 companies |
| Recent activity | 69th | 2 rounds in 12 months |
| Early stage | 100th | 100% of entries at pre-seed or seed |
| Evidence | 98th | 33% of companies confirmed by a round |
| Sector focus | 100th | 100% in its largest sector |
| Reach | 42th | 2 countries |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| Creative Destruction Lab | 2 |
| Lifespan Vision Ventures | 2 |
| Axial | 1 |
| Bold Capital Partners | 1 |
| CARMA Fund | 1 |
| CRV | 1 |
| Civilization Ventures | 1 |
| Cornucopian Capital | 1 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers6100%
- No longer answers00%
- Points to another company00%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 100% | 15% |
Co-investor network
who it backs companies with, and who they back togetherAll co-investors or Compare portfolios with Creative Destruction Lab
Compare Eos BioInnovation head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Recent portfolio activity
when companies last raised with Eos BioInnovation| Date | Company | Stage |
|---|---|---|
| 13 May 2026 | Seed Led | |
| 8 Jan 2026 | Seed |
Round details for Eos BioInnovation
Amounts, full round histories and every co-investor in Eos BioInnovation's rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
6 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| Autoimmunity BioSolutions is developing a therapy to treat autoimmune diseases by targeting a genetic cause of poor treatment response | Healthcare & Biotech | May 2026Seed | Page + round | |
| Axonis Therapeutics develops medicines targeting neurological disorders | Healthcare & Biotech | Portfolio page | ||
| Deciduous Therapeutics develops novel medicines to eliminate senescent cells and treat age-related diseases. | Healthcare & Biotech | Portfolio page | ||
| HDAX Therapeutics develops oral medicines that target HDAC6 for the treatment of various diseases, including renal, cardiometabolic and neurological diseases. | Healthcare & Biotech | Portfolio page | ||
| Regatta Bio is advancing the next generation of regulatory T cell therapies to address challenges in immune health | Healthcare & Biotech | Portfolio page | ||
| TECregen develops therapies targeting thymus regeneration | Healthcare & Biotech | Jan 2026Seed | Page + round |
About this data
site last read 5 Nov 2026- Site
- eosbioinnovation.com
- Last read
- 5 Nov 2026
- Watching since
- 6 Nov 2026
- Rounds since
- 8 Jan 2026
- Companies checked
- 6
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get Eos BioInnovation's profile as data
Pull Eos BioInnovation's portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/eosbioinnovation.com
# also
GET /v1/firms/eosbioinnovation.com/portfolio
GET /v1/firms/eosbioinnovation.com/coinvestors
GET /v1/firms/eosbioinnovation.com/news